In order to provide guidance to hospital pharmacy departments in the prevention and control of Coronavirus SARS-CoV-2 Infection, and further strengthen pharmaceutical and pharmacy services and security, CPA launched CORONAVIRUS 2019-nCoV INFECTION: Expert Consensus on Guidance and Prevention Strategies for hospital pharmacists and the pharmacy workforce (First Edition) on February 6th.
With more awareness and development of prevention and control of this disease, CPA promptly organized experts to revise the Expert Consensus and completed CORONAVIRUS SARS-CoV-2 INFECTION: Expert Consensus on Guidance and Prevention and Control Strategies for Pharmaceutical Work in Hospitals (2nd Edition). Relevant amendments was described as below. It was added that the information of naming this coronaviruses by National Health Commission of the PRC, WHO and International Committee on Taxonomy of Viruses; the dosage and administration of RIBAVIRIN was revised in accordance with Temporary Guidance on Diagnosis and Treatment of Novel Coronavirus Pneumonia ( (5th Edition) revised by National Health Commission of the PRC; the reference list of key therapeutic drugs was revised; information sources, reference and other information were updated.
The revision of the Expert Consensus will help hospital pharmacy departments and workforce to promptly obtain the updated information, better develop the pharmaceutical and pharmacy security for epidemic prevention, improve the quality of pharmaceutical and pharmacy services, promote the safe and rational use of medicines, enhance the self-protection awareness and ability, play more important and positive role of hospital pharmacy service in the prevention and control of CORONAVIRUS SARS-CoV-2 INFECTION.